Skip to main content

Retinopathy of Prematurity clinical trials at UCSF

2 in progress, 1 open to eligible people

Retinopathy of prematurity is a condition that harms the eyes of babies born too early. UCSF is conducting trials to see if bevacizumab, given in low doses, can treat the most severe cases. This research is important for understanding how to care for these vulnerable infants.

Showing trials for
  • Bevacizumab Treatment For Type 1 ROP

    open to eligible people ages up to 6 months

    Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.

    San Francisco, California and other locations

  • Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

    Sorry, accepting new patients by invitation only

    Primary objectives of the study are: - To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP). - To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. Secondary objectives of the study are: - To describe visual function in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. - To describe overall development in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.

    San Francisco, California and other locations

Last updated: